Insider Trading Alert - IPXL, SNCR, CYBX, KLIC And SPW Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 8, 2014, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,000.20 to $12,860,510.00.

Highlighted Stocks Traded by Insiders:

Impax Laboratories (IPXL) - FREE Research Report

Burr Robert L who is Director at Impax Laboratories sold 1,500 shares at $24.31 on Jan. 8, 2014. Following this transaction, the Director owned 43,825 shares meaning that the stake was reduced by 3.31% with the 1,500-share transaction.

The shares most recently traded at $24.49, up $0.18, or 0.73% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:

  • 4-Week # shares sold: 1,500
  • 12-Week # shares sold: 3,000
  • 24-Week # shares sold: 7,500

The average volume for Impax Laboratories has been 468,300 shares per day over the past 30 days. Impax Laboratories has a market cap of $1.7 billion and is part of the health care sector and drugs industry. Shares are down 2.35% year-to-date as of the close of trading on Wednesday.

Impax Laboratories, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and marketing of bioequivalent pharmaceutical products; and development and marketing of branded products. The company has a P/E ratio of 14.5. Currently there are 3 analysts that rate Impax Laboratories a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPXL - FREE

TheStreet Quant Ratings rates Impax Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, notable return on equity, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Synchronoss Technologies (SNCR) - FREE Research Report

Garcia Robert who is President at Synchronoss Technologies sold 468 shares at $30.69 on Jan. 8, 2014. Following this transaction, the President owned 61,158 shares meaning that the stake was reduced by 0.76% with the 468-share transaction.

Doran Patrick Joseph who is EVP & Chief Technology Office at Synchronoss Technologies sold 146 shares at $30.69 on Jan. 8, 2014. Following this transaction, the EVP & Chief Technology Office owned 20,343 shares meaning that the stake was reduced by 0.71% with the 146-share transaction.

Rosenberger Karen who is Chief Accounting Officer at Synchronoss Technologies sold 126 shares at $30.69 on Jan. 8, 2014. Following this transaction, the Chief Accounting Officer owned 12,726 shares meaning that the stake was reduced by 0.98% with the 126-share transaction.

The shares most recently traded at $31.17, up $0.48, or 1.54% since the insider transaction. Historical insider transactions for Synchronoss Technologies go as follows:

  • 4-Week # shares sold: 84,868
  • 12-Week # shares sold: 133,159
  • 24-Week # shares sold: 248,662

The average volume for Synchronoss Technologies has been 432,000 shares per day over the past 30 days. Synchronoss Technologies has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. Shares are up 1.26% year-to-date as of the close of trading on Wednesday.

Synchronoss Technologies, Inc. provides software-based activation and personal cloud solutions for connected devices. The company has a P/E ratio of 110.3. Currently there are 8 analysts that rate Synchronoss Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNCR - FREE

TheStreet Quant Ratings rates Synchronoss Technologies as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Synchronoss Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cyberonics (CYBX) - FREE Research Report

Simpson Randal L who is VP Operations at Cyberonics sold 3,000 shares at $64.89 on Jan. 8, 2014. Following this transaction, the VP Operations owned 45,285 shares meaning that the stake was reduced by 6.21% with the 3,000-share transaction.

Moore Daniel Jeffrey who is President & CEO at Cyberonics sold 4,750 shares at $64.72 on Jan. 8, 2014. Following this transaction, the President & CEO owned 35,140 shares meaning that the stake was reduced by 11.91% with the 4,750-share transaction.

The shares most recently traded at $66.53, up $1.81, or 2.73% since the insider transaction. Historical insider transactions for Cyberonics go as follows:

  • 4-Week # shares sold: 6,500
  • 12-Week # shares sold: 32,411
  • 24-Week # shares sold: 65,361

The average volume for Cyberonics has been 238,600 shares per day over the past 30 days. Cyberonics has a market cap of $1.8 billion and is part of the health care sector and health services industry. Shares are up 1.39% year-to-date as of the close of trading on Wednesday.

Cyberonics, Inc., together with its subsidiaries, engages in the design, development, marketing, and sale of implantable medical devices to hospitals and ambulatory surgery centers. The company has a P/E ratio of 38.4. Currently there are 7 analysts that rate Cyberonics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CYBX - FREE

TheStreet Quant Ratings rates Cyberonics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, growth in earnings per share and increase in stock price during the past year. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Cyberonics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Kulicke & Soffa Industries (KLIC) - FREE Research Report

Guilmart Bruno who is President, CEO at Kulicke & Soffa Industries sold 50,000 shares at $12.96 on Jan. 8, 2014. Following this transaction, the President, CEO owned 517,640 shares meaning that the stake was reduced by 8.81% with the 50,000-share transaction.

The shares most recently traded at $12.95, down $0.01, or 0.11% since the insider transaction. Historical insider transactions for Kulicke & Soffa Industries go as follows:

  • 4-Week # shares sold: 172,702
  • 12-Week # shares sold: 188,702
  • 24-Week # shares sold: 292,025

The average volume for Kulicke & Soffa Industries has been 901,300 shares per day over the past 30 days. Kulicke & Soffa Industries has a market cap of $983.8 million and is part of the technology sector and electronics industry. Shares are down 1.8% year-to-date as of the close of trading on Wednesday.

Kulicke and Soffa Industries, Inc. designs, manufactures, and sells capital equipment and expendable tools to assemble semiconductor devices, including integrated circuits, discrete devices, light-emitting diodes, and power modules. The company has a P/E ratio of 16.6. Currently there are 2 analysts that rate Kulicke & Soffa Industries a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KLIC - FREE

TheStreet Quant Ratings rates Kulicke & Soffa Industries as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full Kulicke & Soffa Industries Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

SPX Corporation (SPW) - FREE Research Report

Lilly Kevin L who is Sr. VP, Sec. and Gen. Counsel at SPX Corporation sold 3,000 shares at $98.32 on Jan. 8, 2014. Following this transaction, the Sr. VP, Sec. and Gen. Counsel owned 100,909 shares meaning that the stake was reduced by 2.89% with the 3,000-share transaction.

The shares most recently traded at $99.06, up $0.74, or 0.75% since the insider transaction. Historical insider transactions for SPX Corporation go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 3,000
  • 24-Week # shares sold: 3,000

The average volume for SPX Corporation has been 235,600 shares per day over the past 30 days. SPX Corporation has a market cap of $4.5 billion and is part of the industrial goods sector and industrial industry. Shares are down 1.23% year-to-date as of the close of trading on Wednesday.

SPX Corporation provides specialized engineered solutions worldwide. It operates in two segments, Flow Technology, and Thermal Equipment and Services. The stock currently has a dividend yield of 1.02%. Currently there are 8 analysts that rate SPX Corporation a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPW - FREE

TheStreet Quant Ratings rates SPX Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, good cash flow from operations, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full SPX Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Impax Shares Jump on Merger Buzz

Impax Shares Jump on Merger Buzz

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Teva, Mylan Seen to Stay on M&A Sidelines

Teva, Mylan Seen to Stay on M&A Sidelines

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva's Massive Debt Load Just Became an Even Bigger Issue